Lydia Scarfò, an expert in chronic lymphocytic leukemia from Milan, and Anna Schuh, a professor from the University of Oxford, share insights on the latest ESMO guidelines for CLL. They delve into diagnostic advancements, highlighting critical biomarkers and clinical practice variations between the US and Europe. The duo discusses evolving treatment strategies focusing on personalized medicine, patient preferences, and the significance of measurable residual disease. They also explore the debate over time-limited versus continuous regimens in enhancing patient outcomes.
